Company Analysis
Sign in

Jazz Pharmaceuticals plc (JAZZ)

Nasdaq: JAZZ · Pharmaceutical Preparations · Dublin · filing with the SEC since 2003
Full chart Alerts Compare
Grade6.3
◀ Past 8.0● Present 6.4▶ Future 4.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

124 patents granted to the 15 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Jazz Pharmaceuticals plc’s names, not what it holds today.

Patents granted
124
123 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
14
Against 11 in 2024 and 5 in 2023
Applications published
203
20 of them in 2025
Names they are printed under
15
a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals43
Organic fine chemistry6
Biotechnology4
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name15 counted
Jazz Pharmaceuticals Ireland Limited a subsidiary
named as the applicant on its applications, in IE. 1 more under the same name are not counted (printed in DE)
0 granted
57 published
Jazz Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
30 granted
22 published
Jazz Pharmaceuticals Ireland Limited a subsidiary
IE, as the owner printed on each patent. 1 more under the same name are not counted (printed in JP)
37 granted
13 published
CHIMERIX, INC. a subsidiary
US, as the owner printed on each patent
28 granted
17 published
Chimerix, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
32 published
JAZZ PHARMACEUTICALS, INC. its own name
named as the applicant on its applications, in US
0 granted
22 published
GENTIUM S.R.L. a subsidiary
named as the applicant on its applications, in IT
0 granted
19 published
Gentium S.p.A. a subsidiary
IT, as the owner printed on each patent
6 granted
10 published
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED a subsidiary
GB, as the owner printed on each patent
15 granted
0 published
GENTIUM S.R.L. a subsidiary
IT, as the owner printed on each patent
7 granted
0 published
Jazz Pharmaceuticals Research UK Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
7 published
GW Pharmaceuticals Limited a subsidiary
GB, as the owner printed on each patent
0 granted
2 published
GW Pharmaceuticals Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
1 published
GW Pharmaceuticals, plc a subsidiary
GB, as the owner printed on each patent
0 granted
1 published
Jazz Pharmaceuticals Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Names not counted (1)
Jazz Pharmaceuticals International Limited
Most of its patents print BM; this name counts in IE. 0 granted and 4 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,447,163Liposomal formulations of Bcl inhibitorsPharmaceuticalsJazz Pharmaceuticals Therapeutics, Inc.
Oct 14, 202512,440,449Alcohol-resistant drug formulationsPharmaceuticalsJazz Pharmaceuticals Ireland Limited
Sep 30, 202512,427,160Use of cannabinoids in the treatment of epilepsyPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Sep 2, 202512,403,136Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereofOrganic fine chemistryJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Aug 26, 202512,396,963Cannabidiol-type cannabinoid compoundPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Aug 12, 202512,383,567Use of cannabinoids in the treatment of epilepsyPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Aug 12, 202512,383,512Cannabidiol-type cannabinoid compoundPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Jul 22, 202512,364,670Cannabidiol-type cannabinoid compoundPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Jul 15, 202512,357,586Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsyPharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Jul 8, 202512,350,253Use of cannabinoids in the treatment of dyskinesia associated with parkinson's diseasePharmaceuticalsJAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387418USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYPharmaceuticalsJazz Pharmaceuticals Research UK Limited
Dec 18, 20252025/0382321MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFOrganic fine chemistryChimerix, Inc.
Dec 18, 20252025/0381152CANNABIDIOL-TYPE CANNABINOID COMPOUNDPharmaceuticalsJazz Pharmaceuticals Research UK Limited
Dec 11, 20252025/0376446CRYSTALINE FORMS OF A SYNTHETIC CANNABINOIDPharmaceuticalsJazz Pharmaceuticals Research UK Limited
Oct 16, 20252025/0320227MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOFPharmaceuticalsJazz Pharmaceuticals Ireland Limited
Sep 18, 20252025/0289774CRYSTALINE FORMS OF A CANNABIDIOL-LIKE CANNABINOIDOrganic fine chemistryJazz Pharmaceuticals Research UK Limited
Aug 21, 20252025/0262228TREATMENT OF SPASTICITY AND PAIN IN RENALLY-IMPAIRED PATIENTSPharmaceuticalsJazz Pharmaceuticals Research UK Limited
Aug 7, 20252025/0248950USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYPharmaceuticalsJazz Pharmaceuticals Research UK Limited · patent 12,427,160 granted from it
Jul 31, 20252025/02419207-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPYPharmaceuticalsCHIMERIX, INC.
Jul 24, 20252025/0236867EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEBiotechnologyGENTIUM S.R.L.
What it applied for, 2024 to 2025: Pharmaceuticals 27 · Organic fine chemistry 6 · Biotechnology 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton JAZZ · research, not advice